Dergiler / Marmara Medical Journal / 2016 / Cilt: 29 - Sayı: 2
Latest updates on chronic viral hepatitis B
- Sayfa
- 33–37
- DOI
- —
Özet
Hepatitis B virus (HBV) remains a major cause of liver-relatedmorbidity and mortality in Turkey and all over the world. Twodifferent types of antiviral agents can be used in the treatmentof chronic hepatitis B (CHB). Conventional (IFN) or pegylatedinterferon alpha (PegIFN), nucleoside [lamivudine (LMV),telbivudine, emtricitabine, entecavir (ETV)] and nucleotide analogs[adefovir dipivoxil (ADV)] and tenofovir disoproxil fumarate(TDF)]. Antiviral agent must ensure a degree of HBV viralsuppression and will lead to biochemical, serological remissionand histological improvement. Current treatment strategies arediscussed in present brief report.Keywords: Chronic hepatitis B, Nucleos(t)ide analog, Entecavir,Tenofovir disoproxil fumarate
Abstract
Hepatitis B virus (HBV) remains a major cause of liver-relatedmorbidity and mortality in Turkey and all over the world. Twodifferent types of antiviral agents can be used in the treatmentof chronic hepatitis B (CHB). Conventional (IFN) or pegylatedinterferon alpha (PegIFN), nucleoside [lamivudine (LMV),telbivudine, emtricitabine, entecavir (ETV)] and nucleotide analogs[adefovir dipivoxil (ADV)] and tenofovir disoproxil fumarate(TDF)]. Antiviral agent must ensure a degree of HBV viralsuppression and will lead to biochemical, serological remissionand histological improvement. Current treatment strategies arediscussed in present brief report.Keywords: Chronic hepatitis B, Nucleos(t)ide analog, Entecavir,Tenofovir disoproxil fumarate